Associations between aflatoxin B₁-albumin adduct levels with metabolic conditions in Guatemala: A cross-sectional study

Christian S. Alvarez¹ | Alvaro Rivera-Andrade² | María F. Kroker-Lobos² | Andrea A. Florio¹,³ | Joshua W. Smith⁴ | Patricia A. Egner⁴ | Neal D. Freedman¹ | Mariana Lazo⁵,⁶ | Eliseo Guallar⁷ | Michael Dean¹ | Barry I. Graubard¹ | Manuel Ramírez-Zea² | Katherine A. McGlynn¹ | John D. Groopman⁴,⁷

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
²INCAP Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala City, Guatemala
³Department of Nutrition, Harvard TH Chan School of Public Health, Harvard University, Boston, Massachusetts, USA
⁴Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
⁵Division of General Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
⁶Urban Health Collaborative, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania, USA
⁷Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

Correspondence
Christian S. Alvarez, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Rockville, Maryland, USA. Email: csalvarezp@gmail.com

Funding Information
Johns Hopkins Bloomberg School of Public Health, Grant/Award Number: T32ES007141; National Cancer Institute, Grant/Award Number: Intramural Program; National Institutes of Health, Grant/Award Numbers: Intramural Research Program, P30CA006973-52S3, #2T32DK007703-26

Abstract

Background and Aims: Metabolic conditions such as obesity, type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) are highly prevalent in Guatemala and increase the risk for a number of disorders, including hepatocellular carcinoma (HCC). Aflatoxin B₁ (AFB₁) levels are also notably elevated in the population and are known to be associated with HCC risk. Whether AFB₁ also contributes to the high prevalence of the metabolic disorders has not been previously examined. Therefore, the purpose of this study was to assess the association between AFB₁ and the metabolic conditions.

Methods: Four-hundred twenty-three individuals were included in the study, in which AFB₁-albumin adduct levels were measured in sera. Metabolic conditions included diabetes, obesity, central obesity, metabolic syndrome, and NAFLD. Crude and adjusted prevalence odds ratios (PORs) and 95% confidence intervals (95% CI) were estimated for the associations between the metabolic conditions and AFB₁-albumin adduct levels categorized into quartiles.

Results: The study found a significant association between AFB₁-albumin adduct levels and diabetes (Q4 vs Q1 POR = 3.74, 95%CI: 1.71-8.19; P-trend .003).

Abbreviations: AFB₁, aflatoxin B₁; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence intervals; FLI, fatty liver index; GGT, Υ-glutamyl transferase; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HSI, hepatic steatosis index; INCAP, Institute of Nutrition of Central America and Panama; IQR, interquartile range; LMICs, low- and middle-income countries; MetSyn, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; OTA, ochratoxin A (OTA); POR, prevalence odds ratios; TE, transient elastography.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
No associations were observed between AFB$_1$-albumin adduct levels and the other conditions.

**Conclusions:** As diabetes is the metabolic condition most consistently linked to HCC, the possible association between AFB$_1$ exposure and diabetes may be of public health importance. Further studies are warranted to replicate the findings and examine potential mechanisms.

**KEYWORDS**
aflatoxin, diabetes, Guatemala, metabolic syndrome, NAFLD, obesity

---

**1 | INTRODUCTION**

Rates of metabolic conditions such as diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) have increased worldwide.$^{1-4}$ The global prevalence of these conditions is estimated to be 9% for diabetes,$^7$ 12% for obesity,$^5$ 25% for metabolic syndrome,$^9$ and 25% for NAFLD,$^4$ and are expected to increase further, particularly in low- and middle-income countries (LMICs).$^{2,3,6,7}$ All the conditions share a number of pathophysiological mechanisms that can lead to cardiovascular complications, chronic renal and liver diseases, cancer, and death.$^8$ Although obesity seems to be the main driver of most metabolic conditions, there are several other factors that could explain their rising global prevalence.$^9$

Aflatoxins are naturally occurring mycotoxins produced by fungi of the *Aspergillus* species, predominantly, *A. flavus* and *A. parasiticus*. $^{10}$ *Aspergillus* contaminates maize, groundnuts, and cottonseed in warm, humid environments around the world.$^{11}$ Aflatoxin B$_1$ (AFB$_1$), the most toxicologically potent of the aflatoxins, was classified as a Group 1 human carcinogen by the International Agency for Research on Cancer in 1993.$^{12}$ AFB$_1$-lysine adducts of serum albumin, a biomarker of internal dose, are strongly associated with the development of hepatocellular carcinoma (HCC), and other health outcomes such as childhood stunting.$^{11,13-15}$ In Guatemala, our group previously reported the finding of high levels of serum AFB$_1$ among adults 40 years and older,$^{16}$ a result consistent with prior evidence of high AFB$_1$ levels in maize samples across the country.$^{17}$ In addition, our group has reported a high prevalence of diabetes (21.6%), obesity (30.9%), central obesity (74.3%), NAFLD (60%), and metabolic syndrome (64.2%) in the same population.$^{18}$ As these metabolic conditions are associated with increased risk of HCC, and Guatemala has the highest rate of HCC in the Western Hemisphere, we speculated that AFB$_1$ could also be associated with the metabolic conditions. Although an examination of AFB$_1$ and metabolic conditions in humans has not been previously reported, a prior animal study found that administration of AFB$_1$ resulted in elevated glucose and cholesterol levels, serological measures associated with the metabolic disorders of interest.$^{19}$

Therefore, the purpose of the current study was to explore the association between AFB$_1$ and metabolic conditions in Guatemala. Assessing the role of prevalent environmental exposures in the development of these conditions is critical to the creation of comprehensive public health measures to reduce the burden of the metabolic disorders and AFB$_1$ exposure in the population.

**2 | METHODS**

**2.1 | Study population**

Four hundred sixty-one individuals were recruited between May and October 2016 from five communities located in the central and western regions of Guatemala: Chichicastenango (Quiché department), Escuintla (Escuintla), Mixco (Guatemala), San Lucas Tolimán (Sololá), and San Pablo Jocopilas (Suchitepéquez). The communities were classified as either urban (Escuintla and Mixco) or rural (Chichicastenango, San Lucas Tolimán and San Pablo Jocopilas). Study recruitment consisted of household visits. In Mixco, households were selected at random from a formal sampling frame, while a nonrandom based sampling method was used in the other four sites. Detailed information on the sampling procedures for the study has previously been published.$^{16}$ Trained study staff visited selected households and invited individuals to participate. Up to two non-genetically related persons of at least 40 years of age were recruited from each household. All participants provided written informed consent. Individuals were excluded if they were pregnant or unable to provide informed consent. The institutional review boards of both the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, USA (IRB #6877) and the Institute of Nutrition of Central America and Panama (INCAP) in Guatemala City, Guatemala (IRB #053-2015) approved the study.

**2.2 | Data collection**

Study participants were interviewed by trained staff using structured questionnaires previously validated by INCAP. The questionnaires included questions on sociodemographic characteristics, lifestyle factors, medical history, access to healthcare, and food consumption. Height, weight, and waist circumference were measured by study staff using standardized instruments and protocols as previously described.$^{18}$ Physical activity was assessed by using the International
Physical Activity Questionnaire short form (IPAQ 6). The methods to categorize the different levels of physical activity have been detailed elsewhere.\textsuperscript{18} Blood samples were obtained by trained phlebotomists using a standard protocol. An eight-hour fast was required prior to the collection of the samples. In total, 444 individuals provided serum samples.

### 2.3 | Laboratory assessments

Fasting glucose was measured in plasma, while total cholesterol, triglycerides, high-density lipoprotein, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and \( \gamma \)-glutamyl transferase (GGT) were measured in serum. All plasma and serum analytes were determined on a Cobas c111 clinical chemistry analyzer (Roche Diagnostics).

The determination of AFB\textsubscript{1}-lys adduct levels in serum was performed by isotope-dilution mass spectrometry. Adduct concentrations (pg/AFB\textsubscript{1}-lys/mL serum) were normalized to total serum albumin and expressed as pg AFB\textsubscript{1}-lys adduct/mg albumin. Details of the laboratory methods have been previously described.\textsuperscript{16} For brevity, AFB\textsubscript{1}-lys adducts/mg albumin is denoted as AFB\textsubscript{1}-albumin adducts throughout the manuscript. In total, 443 samples were of sufficient volume for AFB\textsubscript{1} assessment.

Seropositivity for hepatitis B virus (HBV) was determined by the presence of hepatitis B virus surface antigen (HBsAg) and seropositivity for hepatitis C virus (HCV) was determined by the presence of hepatitis C virus antibodies (anti-HCV). HBsAg and anti-HCV were assessed in the Hepatitis Diagnostic Laboratory of Hannover Medical School as previously described.\textsuperscript{20}

### Table 1 Characteristics of the study population (n = 423)

| Characteristic                                | Median  | IQR*       |
|----------------------------------------------|---------|------------|
| Age (years)                                  | 54      | (47, 62)   |
| BMI (kg/m\textsuperscript{2})                | 27.5    | (24.0, 30.9) |
| AFB\textsubscript{1} (pg/mg albumin)         | 8.5     | (3.8, 22.3) |
| Sex                                          | n       | %          |
| Women                                        | 253     | (59.8)     |
| Men                                          | 170     | (40.2)     |
| Residence                                    |         |            |
| Rural                                        | 262     | (61.9)     |
| Urban                                        | 161     | (38.1)     |
| Ethnicity, self-reported                     |         |            |
| Non-indigenous                               | 189     | (44.8)     |
| Indigenous                                   | 233     | (55.2)     |
| Missing                                      | 1       |            |
| Education                                    |         |            |
| <6 years                                     | 287     | (67.9)     |
| \( \geq \) 6 years                          | 136     | (32.1)     |
| Household income                             |         |            |
| <400 USD/mo.                                 | 311     | (74.0)     |
| \( \geq \) 400 USD/mo.                      | 109     | (26.0)     |
| Missing                                      | 3       |            |
| Alcohol intake\textsuperscript{b}            |         |            |
| Never                                        | 123     | (29.1)     |
| Former                                       | 214     | (50.6)     |
| Current                                      | 86      | (20.3)     |
| Smoking                                      |         |            |
| Never                                        | 246     | (58.2)     |
| Former                                       | 144     | (34.0)     |
| Current                                      | 33      | (7.8)      |
| Physical activity                            |         |            |
| Low                                          | 222     | (52.5)     |
| Moderate                                     | 146     | (34.5)     |
| High                                         | 55      | (13.0)     |
| Elevated fatty liver index                   |         |            |
| No                                           | 163     | (39.4)     |
| Yes                                          | 251     | (60.6)     |
| Missing                                      | 9       |            |
| Elevated hepatic steatosis index             |         |            |
| No                                           | 152     | (36.5)     |
| Yes                                          | 264     | (63.5)     |
| Missing                                      | 7       |            |
| Elevated ALT or AST levels                   |         |            |
| No                                           | 291     | (68.8)     |
| Yes                                          | 132     | (31.2)     |
| Metabolic syndrome                           |         |            |
| No                                           | 149     | (35.5)     |
| Yes                                          | 271     | (64.5)     |
| Missing                                      | 3       |            |

\*Interquartile range: Q1, Q3.

\textsuperscript{b}Low-to-moderate alcohol consumption <7 drinks per week among women and <14 drinks per week among men.
2.4 | Metabolic conditions definitions

The focus of the investigation was on metabolic conditions; therefore, individuals were excluded from the analysis if they were HBsAg and/or anti-HCV positive (n = 6), or if they reported high alcohol consumption levels defined by drinking ≥7 drinks/week among women, and ≥14 drinks/week among men (n = 14). As HBV, HCV and excessive alcohol consumption were exclusionary criteria, the results for fatty liver disease in the current study are referred to as NAFLD.

Body mass index (BMI) was calculated as weight in kg divided by height in meters squared (kg/m²), with BMI ≥30 kg/m² considered to be obese. Abdominal obesity was defined using two measures; elevated waist circumference (≥90 cm among men and ≥80 cm among women) and elevated waist-to-height ratio (>0.50). Diabetes was defined by self-report of a physician’s diagnosis (86%) and/or measured fasting glucose ≥126 mg/dL (14%). Metabolic syndrome was defined as elevated waist circumference plus at least two of the following factors: serum triglycerides >150 mg/dL, low HDL (<40 mg/dL in men and <50 mg/dL in women), blood pressure >130/85 mmHg, and/or serum glucose >100 mg/dL. Diabetes was defined by self-report of a physician’s diagnosis (86%) and/or measured fasting glucose ≥126 mg/dL (14%). Metabolic syndrome was defined as elevated waist circumference plus at least two of the following factors: serum triglycerides >150 mg/dL, low HDL (<40 mg/dL in men and <50 mg/dL in women), blood pressure >130/85 mmHg, and/or serum glucose >100 mg/dL.21 NAFLD was estimated by several methods; the fatty liver index (FLI), the hepatic steatosis index (HSI), and by the presence of elevated levels of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST). FLI was calculated as: 

$$FLI = \frac{e^{0.953 \times \log(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \log(\text{GGT}) + 0.053 \times \text{waist circumference} - 15.745)}{1 + e^{0.953 \times \log(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \log(\text{GGT}) + 0.053 \times \text{waist circumference} - 15.745} \times 100$$

An FLI ≥60 was considered elevated. HSI was calculated as: 8 × (ALT/AST ratio) + BMI (+2, if female; +2, if
**Table 3** Prevalence odds ratios (POR) and 95% confidence intervals (CI) for the associations between AFB1-albumin adduct levels (pg/mg) and the metabolic conditions

| AFB1 | Non-case/case | Crude model | Adjusted model |  |
|------|---------------|-------------|----------------|---|
|      | POR | 95% CI | POR | 95% CI |  |
| **Diabetes** | | | | | |
| AFB-Q1 | 85/20 | 1.00 (referent) | 1.00 (referent) | | |
| AFB-Q2 | 84/22 | 1.11 (0.58, 2.15) | 1.18 (0.57, 2.44) | | |
| AFB-Q3 | 82/22 | 1.14 (0.57, 2.26) | 1.51 (0.73, 3.11) | | |
| AFB-Q4 | 79/26 | 1.40 (0.71, 2.76) | 3.74 (1.71, 8.19) | | |
| **P-value for trend** | .35 | .003 | | | |
| **Metabolic syndrome** | | | | | |
| AFB-Q1 | 38/67 | 1.00 (referent) | 1.00 (referent) | | |
| AFB-Q2 | 29/77 | 1.51 (0.85, 2.68) | 2.30 (1.04, 5.07) | | |
| AFB-Q3 | 31/73 | 1.34 (0.74, 2.40) | 1.85 (0.84, 4.09) | | |
| AFB-Q4 | 51/54 | 0.60 (0.34, 1.05) | 1.74 (0.80, 3.78) | | |
| **P-value for trend** | .07 | .25 | | | |
| **Obesity** | | | | | |
| AFB-Q1 | 67/37 | 1.00 (referent) | 1.00 (referent) | | |
| AFB-Q2 | 65/40 | 1.11 (0.64, 1.93) | 1.14 (0.61, 2.12) | | |
| AFB-Q3 | 74/30 | 0.73 (0.41, 1.28) | 0.83 (0.43, 1.59) | | |
| AFB-Q4 | 83/23 | 0.51 (0.28, 0.94) | 0.92 (0.44, 1.90) | | |
| **P-value for trend** | .01 | .61 | | | |
| **Elevated waist circumference** | | | | | |
| AFB-Q1 | 20/84 | 1.00 (referent) | 1.00 (referent) | | |
| AFB-Q2 | 24/82 | 0.85 (0.44, 1.65) | 1.04 (0.45, 2.38) | | |
| AFB-Q3 | 21/83 | 0.90 (0.48, 1.71) | 1.16 (0.56, 2.40) | | |
| AFB-Q4 | 42/64 | 0.38 (0.21, 0.71) | 0.91 (0.44, 1.88) | | |
| **P-value for trend** | .002 | .84 | | | |
| **Elevated waist-to-height ratio** | | | | | |
| AFB-Q1 | 3/101 | 1.00 (referent) | 1.00 (referent) | | |
| AFB-Q2 | 7/99 | 0.42 (0.11, 1.68) | 0.71 (0.15, 3.30) | | |
| AFB-Q3 | 4/99 | 0.74 (0.16, 3.42) | 1.39 (0.28, 6.87) | | |
| AFB-Q4 | 7/99 | 0.42 (0.11, 1.67) | 1.01 (0.25, 4.00) | | |
| **P-value for trend** | .36 | .69 | | | |
| **Elevated fatty liver index** | | | | | |
| AFB-Q1 | 35/69 | 1.00 (referent) | 1.00 (referent) | | |
| AFB-Q2 | 31/74 | 1.21 (0.67, 2.18) | 1.70 (0.72, 3.97) | | |
| AFB-Q3 | 37/63 | 0.76 (0.44, 1.34) | 1.10 (0.51, 2.40) | | |
| AFB-Q4 | 60/45 | 0.38 (0.22, 0.68) | 0.72 (0.30, 1.75) | | |
| **P-value for trend** | <.001 | .29 | | | |
| **Elevated hepatic steatosis index** | | | | | |
| AFB-Q1 | 36/68 | 1.00 (referent) | 1.00 (referent) | | |
| AFB-Q2 | 32/73 | 1.21 (0.67, 2.17) | 1.88 (0.65, 5.48) | | |
| AFB-Q3 | 32/70 | 1.16 (0.64, 2.09) | 1.66 (0.59, 4.64) | | |
| AFB-Q4 | 52/53 | 0.54 (0.30, 0.97) | 1.42 (0.47, 4.26) | | |
| **P-value for trend** | .04 | .60 | | | |

(Continues)
diabetes mellitus). An HSI score >36 was considered elevated. AST levels >41 U/L among men and >33 U/L among women were considered to be elevated, while ALT levels >40 U/L among men and >32 U/L among women were considered to be elevated. Prior research in a U.S. Hispanic/Latino population has used elevated ALT/AST levels, in the absence of viral infection or excessive alcohol intake, as a proxy measure of NAFLD.

### 2.5 Statistical analysis

Descriptive statistics, including medians for the continuous variables and frequencies for the categorical variables, were computed. In addition, median and interquartile ranges (IQRs) of AFB1-albumin adducts were computed. Descriptive statistics, including medians for the continuous variables and frequencies for the categorical variables, were computed. The generalized estimated equation method with the mean model based on logistic regression and an independence working correlation matrix was used to estimate the prevalence odds ratios (POR) and 95% confidence intervals (CI) for the associations between the metabolic conditions and AFB1-albumin adduct levels by quartiles. A dose-response relation between the metabolic conditions and AFB1-albumin adducts was calculated by scoring the quartiles as 1 through 4 and including the score as a continuous variable in the models. Multivariable-adjusted models were examined using stepwise regression and included age, sex, residence (urban, rural), indigenous (self-reported indigenous vs no indigenous), smoking (never, former, current), low-to-moderate alcohol intake (never, former, current), physical activity (low, moderate, intense) and BMI for all conditions other than obesity and the measures of central obesity. Since this is an exploratory analysis, no adjustment for multiple comparisons was done.

In addition to the main analysis, PORs and 95% CIs were estimated to assess associations between total maize and tortilla consumption with each metabolic condition.

All tests of significance were two-sided. *P*-values less than .05 were considered statistically significant without adjustment for multiple comparisons as the analyses were exploratory. Statistical analyses were conducted in SAS version 9.4 (SAS Institute, Cary, North Carolina).

### 3 RESULTS

Table 1 shows the characteristics of the 423 study participants. The median age was 54 years (interquartile range [IQR] 47, 62 years), 61.9% resided in rural communities and 55.2% self-identified as indigenous. A majority (74.0%) of participants had a monthly income of less than US$400 and 67.9% had completed less than 6 years of schooling. In addition, 20.3% were current drinkers of low-to-moderate amounts of alcohol, while 7.8% were current smokers. The median BMI was 27.5 kg/m² and 52.5% of participants reported low levels of physical activity.

The prevalence of NAFLD in the population varied depending on the index used: 60.6% of the participants had an elevated FLI, 63.5% had an elevated HSI and 31.2% had an elevated ALT or AST level. The prevalence of metabolic syndrome was 64.5% while the prevalence of diabetes was 21.4%. The anthropometric measures indicated that 30.7% of the population were obese, 74.5% had an elevated waist circumference and 95.0% had an elevated waist-to-height ratio. The median AFB1 level was 8.5 pg/mg albumin.

Table 2 displays the median AFB1-albumin adduct levels by participants’ characteristics. The median levels were higher among men (11.4 pg/mg albumin), persons less than age 50 (10.8 pg/mg albumin), residents of rural communities (14.0 pg/mg albumin), self-reported indigenous persons (13.7 pg/mg albumin), persons with less than 6 years of education (11.7 pg/mg albumin) and persons who earned less than $400 per month (10.4 pg/mg). In addition, the median AFB1 level was higher among individuals with high levels of physical activity (20.3 pg/mg albumin). In contrast, the median level of AFB1 (7.2 pg/mg albumin) was lower among individuals with BMI ≥30 kg/m². Individuals with NAFLD (determined by elevated FLI, elevated HSI, or elevated ALT/AST), metabolic syndrome, obesity, elevated waist circumference, and elevated waist-to-height ratio also had lower median AFB1 levels than did other persons. In contrast, the median level of AFB1 was slightly higher among individuals with diabetes.

The associations between quartiles of AFB1-albumin adduct levels and the metabolic conditions are shown in Table 3. AFB1-albumin adduct levels were significantly associated with diabetes in the adjusted model (Q4 vs Q1 POR: 3.74, 95% CI: 1.71-8.19; P-trend...
Further examination of whether the relationship between AFB1 and diabetes differed by obesity found no significant difference (P value = .94). In addition, the examination of maize and tortilla consumption in relationship to the metabolic conditions identified no significant associations (Table S1).

4 | DISCUSSION

The current study found a potential association between AFB1-albumin adduct levels and diabetes. No significant associations were observed, however, between AFB1-albumin adduct levels and NAFLD, obesity, central obesity, or metabolic syndrome.

To our knowledge, this is the first study to provide evidence of an association between AFB1 and diabetes in humans. Several animal studies, however, have demonstrated that mycotoxin exposure may play a role in the development of diabetes. For example, a recent study in female rats reported that long-term exposure to Ochratoxin A (OTA), a mycotoxin similar to AFB1, increases glucose levels and decreases insulin levels. In addition, OTA may cause damage to the Langerhans islet cells of the pancreas. Similarly, a study in chicks demonstrated elevated levels of glucose after administration of intraperitoneal OTA. The results are consistent with a rodent study that examined penitrem A, a potent mycotoxin elaborated by Aspergillus and other species, that has diabetogenic effects. Furthermore, a study that evaluated long-term exposure to AFB1 on the development of type 1 diabetes in mice, found decreased levels of major urinary protein 1, an indicator of increased insulin sensitivity. In addition, studies have reported that mycotoxins may exert a synergistic effect with other contaminants. Specifically, a study of male rats that examined the effects of OTA and the organochlorine insecticide, endosulfan, reported elevations in glucose levels and in liver enzyme (AST, ALT) levels after administration.

Why mycotoxins would cause diabetes in humans is not clear as there are limited human data. It has been suggested that AFB1, in addition to its well-known mutagen and carcinogen effects, may also act as an endocrine disruptor. For example, a study reported that AFB1 had effects on genes (eg, CYP19A1) important in endocrine regulation in placental cells. Furthermore, a population study of AFB1-exposed workers in a flour mill reported that AFB1 was associated with altered levels of both gonadotropins and gonadal hormones. Other studies have suggested that AFB1 interferes with endocrine function by disrupting enzymes and substrates that are responsible for the synthesis of various hormones. Endocrine disruptors are known to be associated with elevated fasting insulin, increased body mass index, and reduced cognitive and neurodevelopment. In addition, there is accumulating evidence that endocrine disruptors may interfere with epigenetic, structural and functional pathways that are involved in the regulation of lipid metabolism and adipogenesis, which may induce insulin resistance.

Mycotoxins could also be related to the development of diabetes by causing dysbiosis of the gut microbiome, leading to dysregulation of intestinal function and impaired immune responses. Gut dysbiosis may reshape intestinal barrier functions and host metabolic and signaling pathways, which are directly or indirectly related to the insulin resistance in diabetes. Several studies have reported that dysbiosis of the gut microbiome plays a role in the rapid progression of insulin resistance in diabetes. A recent rodent study demonstrated disruption of the gut microbial metabolism after 2-weeks of oral AFB1 exposure. A similar study among mice demonstrated that AFB1 could alter the gut microbiome in a dose-response manner. The authors suggested that AFB1 can induce adverse changes of the community structure of gut microbiota and significant disruption of multiple metabolic pathways that play a role in gluconeogenesis, the Krebs cycle, and lactic acid production.

It is possible that AFB1 in the current analysis was simply acting as a proxy variable for maize or tortilla consumption. However, this hypothesis is not supported by the lack of significant findings in the maize-diabetes and tortilla-diabetes analyses. The results suggest that AFB1 is potentially associated with diabetes, independent of the high level of maize consumption.

In contrast to the findings of the current study, it has been previously suggested that exposure to AFB1 could lead to hepatic steatosis and steatohepatitis. A number of animal studies have demonstrated parenchymal changes including fatty liver, as well as changes in size and morphology of the liver after consumption of AFB1. A study that administered aflatoxin (1 mg/kg of feed) to chickens found the characteristic effects of aflatoxicosis, including yellow liver, became evident after 56 days on study. Another study that evaluated the effects of AFB1 and AFB2 contaminated corn on hepatic function of chickens, found the development of pathological lesions in the liver, changes in serum biochemical parameters (eg, ALT, AST, GGT), and damage to hepatic antioxidant function. It is possible, of course, that the current study was unable to detect an AFB1-NAFLD association due to the use of proxy measures of NAFLD rather than clinical measures such as imaging or liver biopsy. None of the metabolic conditions, other than diabetes, were diagnosed by a physician in this study. Moreover, mechanisms underlying conditions such as NAFLD are not fully understood, and it is likely that hidden mechanisms will be discovered in the near future.

It has been proposed that the nuclear factor erythroid 2 p45-related factor 2 (NRF2) in response to oxidative stress, activates the expression and production of antioxidant enzymes leading to the reduction of aflatoxin levels. Obese individuals exhibit increases in systemic oxidative stress that activate NRF2, which upregulates genes encoding important cytoprotective enzymes, including the glutathione S-transferases (GST). Thus, it is possible that GSTs divert activated aflatoxin away from albumin binding. This is not implying that being obese is “protective,” but it is potentially pointing to a change in the underlying metabolic condition that could affect the biomarker level. It is likely that obese middle-aged adults have been obese for a number of years, hence their obesity would have a long-term impact on metabolism whereas diabetics may be a more recent and shorter-term “exposure.” Finally, while speculative,
since aflatoxins have been demonstrated to partition into fat such as found in the fat layer in milk, it is possible that obese individuals sequester some of the absorbed aflatoxin which would result in diminished bioavailability for metabolic conversion to albumin adducts.\textsuperscript{44} This sequestration in body fat has been demonstrated with other contaminants. For example, a study that measured changes in serum concentrations of lipophilic persistent organic pollutants (POPs) in individuals who underwent bariatric surgery, found an increase in POP serum concentration of POP previously sequestered in adipose tissue. The authors highlighted the potential release and redistribution of POPs after a large and rapid weight loss to other lipid-rich organ such as the brain, kidney, and liver.\textsuperscript{45}

It is noteworthy to mention that in risk assessment there is the assumption that there is no threshold level that constitutes a “safe” or “normal” level of exposure. AFB\textsubscript{1}-lys adducts are biomarkers of internal dose that reflect the formation of mutagenic AFB\textsubscript{1}-DNA adducts and the risk of liver cancer and other health outcomes increase with the level of aflatoxin exposure.\textsuperscript{16}

The strengths of the current study include the use of a robust biomarker of AFB\textsubscript{1} exposure, and the use of comprehensive questionnaires that permitted the adjustment for important covariates, including sociodemographic, lifestyle, and clinical factors. The study also had some limitations. The cross-sectional design precluded the examination of a temporal relationship between AFB\textsubscript{1} and the metabolic conditions. In addition, AFB\textsubscript{1} biomarker levels were determined in a single sample, which may not have accurately reflected cumulative AFB\textsubscript{1} exposure over time. However, it is unlikely that AFB\textsubscript{1} exposure varied greatly over time, as maize is the most important dietary staple in Guatemala and is the crop most likely to be contaminated by AFB\textsubscript{1}.\textsuperscript{17} Another limitation is that liver fat indices, rather than clinical measures were used to estimate NAFLD, and the indices are not as specific or sensitive as other diagnostic tools such as magnetic resonance imaging, ultrasound, or transient elastography (TE). The performance of the indices, however, has been validated previously in other populations. Moreover, our group recently found good agreement between NAFLD by liver indices (FLI and HSI) and NAFLD by TE in the U.S. National Health and Nutrition Examination Survey.\textsuperscript{46} The percent agreement for FLI and TE was 75.1\% and for HSI and TE was 74.3\%. In population studies where imaging of participants is not feasible, the use of FLI and HSI are reasonable substitutes to assess NAFLD, as the indices can be calculated easily and are based on affordable tests.

In conclusion, the current study found that AFB\textsubscript{1} was potentially associated with diabetes. Underlying mechanisms for the association are not fully elucidated, thus, further studies are warranted to confirm the findings and explain potential mechanisms.

**ACKNOWLEDGMENT**

All participants of the study.

**FUNDING**

This work was supported by the National Institutes of Health (NIH) grants P30CA006973-52S3, T32ES007141 (departmental award, supported Joshua W. Smith) and #2T32DK007703-26 (NIH training grant in academic nutrition, supported Andrea A. Florio), and the Intramural Research Program, National Cancer Institute at NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**CONFLICT OF INTEREST**

The authors declare no potential conflict of interest.

**AUTHOR CONTRIBUTIONS**

Conceptualization: Christian S. Alvarez, Katherine A. McGlynn, John D. Groopman.

Data Curation: Alvaro Rivera-Andrade, María F. Kroker-Lobos.

Formal Analysis: Christian S. Alvarez, Barry I. Graubard.

Funding Acquisition: Katherine A. McGlynn, John D. Groopman.

Investigation: Christian S. Alvarez, Alvaro Rivera-Andrade, María F. Kroker-Lobos, Joshua W. Smith, Patricia A. Egner.

Project Administration: Eliseo Guallar, Manuel Ramírez-Zea, Katherine A. McGlynn, John D. Groopman.

Supervision: Eliseo Guallar, Manuel Ramírez-Zea, Katherine A. McGlynn, John D. Groopman.

Visualization: Christian S. Alvarez.

Writing - Original Draft Preparation: Christian S. Alvarez.

Writing - Review & Editing: Alvaro Rivera-Andrade, María F. Kroker-Lobos, Andrea A. Florio, Joshua W. Smith, Patricia A. Egner, Neal D. Freedman, Mariana Lazo, Eliseo Guallar, Michael Dean, Barry I. Graubard, Manuel Ramirez-Zea, Katherine A. McGlynn, John D. Groopman.

All authors have read and approved the final version of the manuscript.

Christian S. Alvarez, the corresponding author, had full access to all the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

**TRANSPARENCY STATEMENT**

The lead author: Christian S. Alvarez, affirms that this manuscript is honest, accurate, and transparent account of the study being reported; no aspects of the study have been omitted; any discrepancies from the study as planned have been explained.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ETHICS STATEMENT**

Approval for the present work was obtained from both the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, USA (IRB #6877) and the Institute of Nutrition of Central America and Panama (INCAP) in Guatemala City, Guatemala (IRB #053-2015). All participants provided informed consent.

**ORCID**

Christian S. Alvarez  
https://orcid.org/0000-0002-5338-0444
REFERENCES

1. Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288-298.
2. Standl E, Khunti K, Hansen TB, Schnell O. The global epideimics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019;26(2_suppl):7-14.
3. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12.
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
5. Collaborators GBDO, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-27.
6. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356(3):213-215.
7. Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70(3):531-544.
8. Alegria E, Casalino G, Castellano C, Alegria B. Obesity, metabolic syndrome and diabetes: cardiovascular implications and therapy. Rev Esp Cardiol. 2008;61(7):752-764.
9. Godoy-Matos AF, Silva Junior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60.
10. Kensler TW, Roeuck BD, Wogan GN, Groopman JD. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci. 2011;120(Suppl 1):528-548.
11. Wu F, Groopman JD, Pestka JJ. Public health impacts of foodborne mycotoxins. Annu Rev Food Sci Technol. 2014;5:351-371.
12. Anonymous. Review. Aflatoxins. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. Lyon, France: IARC; 1993:245-395.
13. Khlangwiset P, Shepard GS, Wu F. Aflatoxins and growth impairment: a review. Crit Rev Toxicol. 2011;41(9):740-755.
14. Wogan GN, Kensler TW, Groopman JD. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(2):249-257.
15. Effects of Aflatoxins and Fumonisins on Child Growth, Mycotoxin Control in Low- and Middle-Income Countries. International Agency for Research on Cancer WHO. 2015.
16. Smith JW, Kroker-Lobos MF, Lazo M, et al. Aflatoxin and viral hepatitis exposures in Guatemala: molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS One. 2017;12(12):e0189255.
17. Torres O, Matute J, Gelineau-van Waes J, et al. Human health implications from co-exposure to aflatoxins and fumonisins in maize-based foods in Latin America: Guatemala as a case study. World Mycotoxin J. 2015;8(2):143-159.
18. Rivera-Andrade A, Kroker-Lobos MF, Lazo M, et al. High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: a population-based study. Nutr Metab Cardiovasc Dis. 2019;29(2):191-200.
19. Maurice DV, Bodine AB, Rehrer NJ. Metabolic effects of low aflatoxin B1 levels on broiler chickens. Appl Environ Microbiol. 1983;45(3):980-984.
20. Heidrich B, Cetindere A, Beyaz M, et al. High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. Eur J Gastroenterol Hepatol. 2014;26(10):1090-1097.
21. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13(3):275-286.
22. Federation ID. IDF Consensus Worldwide Definition of the Metabolic Syndrome. 2006.
23. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
24. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503-508.
25. Kallwitz ER, Daviglus ML, Allison MA, et al. Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by clinic. Clin Gastroenterol Hepatol. 2015;13(3):569-576.
26. Kroker-Lobos MF, Alvarez CS, Rivera-Andrade A, et al. Association between aflatoxin-albumin adduct levels and tortilla consumption in Guatemalan adults. Toxicol Rep. 2019;6:465-471.
27. Mor F, Sengul O, Topsakal S, Kilic MA, Ozmen O. Diabetogenic effects of Ochratoxin a in female rats. Toxins (Basel). 2017;9(4):144.
28. Subramaniam S, Govindasamy S. A-Orchaceus toxicity on carbohydrate-metabolism in chicks. Curr Sci. 1985;54(17):860-862.
29. Suseela R, Shanmugasundaram ERB, Shanmugasundaram KR. Effect of Penicret A on glucose-tolerance studied in rats. Curr Sci. 1986;52:98-100.
30. Tsai FJ, Chen SY, Liu YC, Liao HY, Chen CJ. The comparison of CHCA solvent compositions for improving LC-MALDI performance and its application to study the impact of aflatoxin B1 on the liver proteome of diabetes mellitus type 1 mice. PloS One. 2017;12(7):e0181423.
31. Kumar SN, Telang AG, Singh K, Bastia B. Toxic manifestation of endosulfan and ochratoxin- a in adult male rats. MOJ Toxicol. 2015;1(3):96-101.
32. Storvik M, Huuskonen P, Kyllonen T, et al. Aflatoxin B1–a potential endocrine disruptor–up-regulates CYP19A1 in JEG-3 cells. Toxicol Lett. 2011;202(3):161-167.
33. Beshir S, Shaheen W, Saad-Hussein A, Saeed Y. Aflatoxin B1 as an endocrine disruptor among miller flour workers. SEEJPH. 2020;04:1-12.
34. Bbosa GS, Kitya D, Lubega A, Ogwal-Ongkew JWA, Kyeogome D. Review of the biological and health effects of aflatoxins on body organs and body systems. Dermatol Int. 2013:239–265.
35. Owino VO, Cornelius C, Loechl CU. Elucidating adverse nutritional implications of exposure to endocrine-disrupting chemicals and Mycotoxins through stable isotope techniques. Nutrients. 2018;10(4):401.
36. Liew WP, Mohd-Redzwan S, Mycotoxin: its impact on gut health and microbiota. Front Cell Infect Microbiol. 2018;8:60.
37. Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. 2019;63:101-108.
38. Zhou J, Tang L, Wang J, Wang JS. Aflatoxin B1 disrupts gut-microbial metabolisms of short-chain fatty acids, long-chain fatty acids, and bile acids in male F344 rats. Toxicol Sci. 2018;164(2):453-464.
39. Wang J, Tang L, Glenn TC, Wang JS. Aflatoxin B1 induced compositional changes in gut microbial communities of male F344 rats. Toxicol Sci. 2016;150(1):54-63.
40. Siloto EV, Oliveira EF, Sartori JR, et al. Lipid metabolism of commercial layers fed diets containing aflatoxin, fumonisin, and a binder. Poult Sci. 2013;92(8):2077-2083.
41. Yang J, Bai F, Zhang K, et al. Effects of feeding corn naturally contaminated with aflatoxin B1 and B2 on hepatic functions of broilers. Poult Sci. 2012;91(11):2792-2801.
42. Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy. J Clin Med. 2019;9(1):15.
43. Vasileva LV, Savova MS, Amirova KM, Dinkova-Kostova AT, Georgiev MI. Obesity and NRP2-mediated cytoprotection: where is the missing link? Pharmacol Res. 2020;156:104760.
44. Eaton DL, Groopman JD. The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance. San Diego: Academic Press, Inc.; 1994.
45. Brown RH, Ng DK, Steele K, Schweitzer M, Groopman JD. Mobilization of environmental toxicants following bariatric surgery. Obesity (Silver Spring). 2019;27(11):1865-1873.
46. Jones GS, Alvarez CS, Graubard BI, McGlynn KA. Agreement between the prevalence of nonalcoholic fatty liver disease determined by transient Elastography and fatty liver indices. Clin Gastroenterol Hepatol. 2022;20(1):227–229.e2.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Alvarez CS, Rivera-Andrade A, Kroker-Lobos MF, et al. Associations between aflatoxin B1-albumin adduct levels with metabolic conditions in Guatemala: A cross-sectional study. Health Sci Rep. 2022;5: e495. doi:10.1002/hsr2.495